<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECT: <z:chebi fb="68" ids="48706">Antagonists</z:chebi> of the <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> IIb/IIIa (GPIIb/IIIa) receptor complex are currently used for the treatment of <z:hpo ids='HP_0011009'>acute</z:hpo> coronary syndromes </plain></SENT>
<SENT sid="1" pm="."><plain>The platelet GPIIb/IIIa mediates platelet aggregation, and blocking this receptor complex can reduce or prevent <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>To study the recanalization efficacy of a GPIIb/IIIa <z:chebi fb="68" ids="48706">antagonist</z:chebi> in treating <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, we investigated the therapeutic effects of murine 7E3 F(ab'), in a focal embolic <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> model in rats </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was produced by introducing an autologous <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> into the right side of the middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) </plain></SENT>
<SENT sid="4" pm="."><plain>Thirty male Wistar rats were randomly divided into three groups of 10 rats each: control, 7E3 F(ab')2 administered 1 hour postischemia, and 7E3 F(ab')2 administered 3 hours postischemia </plain></SENT>
<SENT sid="5" pm="."><plain>Animals in the therapeutic groups received intravenous infusion of 6 mg/kg 7E3 F(ab')2 at 1 or 3 hours following cerebral embolization </plain></SENT>
<SENT sid="6" pm="."><plain>Brain <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, neurobehavioral scores, duration of <z:mp ids='MP_0001914'>bleeding</z:mp>, and findings on angiograms of the <z:chebi fb="70" ids="34342">MCA</z:chebi> (before and after infusion) were assessed in <z:hpo ids='HP_0000001'>all</z:hpo> animals </plain></SENT>
<SENT sid="7" pm="."><plain>Angiographic evaluation revealed full <z:chebi fb="70" ids="34342">MCA</z:chebi> recanalization in three of 10 animals in each 7E3 F(ab')2 treatment group </plain></SENT>
<SENT sid="8" pm="."><plain>Animals in these groups exhibited a significant reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume when compared with animals in the control group: 1) <z:mpath ids='MPATH_124'>infarct</z:mpath> volume 1 hour postischemia, 22 +/- 13.9% (p = 0.005); 2) <z:mpath ids='MPATH_124'>infarct</z:mpath> volume 3 hours postischemia, 22.1 +/- 14.8% (p = 0.008); and 3) <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in control animals, 42.4 +/- 16% </plain></SENT>
<SENT sid="9" pm="."><plain>Postischemia treatment with 7E3 F(ab')2 also improved the animal's neurobehavioral performance </plain></SENT>
<SENT sid="10" pm="."><plain>The duration of <z:mp ids='MP_0001914'>bleeding</z:mp> significantly increased by more than two times, but there was no associated increase in <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo> in any group </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: On the basis of their findings, the authors conclude that murine 7E3 F(ab'), is a potent and safe antiplatelet agent in this experimental focal embolic <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> model </plain></SENT>
<SENT sid="12" pm="."><plain>Neuronal lesions were significantly reduced when the treatment was delayed up to 3 hours </plain></SENT>
</text></document>